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Thirteen dengue virus-specific, cytotoxic CD4+ CD8- T-cell clones were established from a donor who was
infected with dengue virus type 3. These clones were examined for virus specificity and human leukocyte
antigen (HLA) restriction in cytotoxic assays. Six patterns of virus specificities were determined. Two
serotype-specific clones recognized only dengue virus type 3. Two dengue virus subcomplex-specific clones
recognized dengue virus types 2, 3, and 4, and one subcomplex-specific clone recognized dengue virus types 1,
2, and 3. Four dengue virus serotype-cross-reactive clones recognized dengue virus types 1, 2, 3, and 4. One
flavivirus-cross-reactive clone recognized dengue virus types 1, 2, 3, and 4 and West Nile virus (WNV), but did
not recognize yellow fever virus (YFV), whereas three flavivirus-cross-reactive clones recognized dengue virus
types 1, 2, 3, and 4, WNV, and YFV. HLA restriction in the lysis by these T-cell clones was also heterogeneous.
HLA-DP, HLA-DQ, and HLA-DR were used as restriction elements by various T-cell clones. We also examined
the recognition of viral nonstructural protein NS3, purified from cells infected with dengue virus type 3 or
WNV, by these T-cell clones. One serotype-specific clone, two dengue virus subcomplex-specific clones, and
three dengue virus serotype-cross-reactive clones recognized NS3 of dengue virus type 3. One flavivirus-cross-
reactive clone recognized NS3 of dengue virus type 3 and WNV. These results indicate that heterogeneous
dengue virus-specific CD4+ cytotoxic T cells are stimulated in response to infection with a dengue virus and that
a nonstructural protein, NS3, contains multiple dominant T-cell epitopes.
Dengue virus infection induces two types of symptoms:
dengue fever and dengue hemorrhagic fever (DHF)-dengue
shock syndrome (DSS) (7, 8). Dengue fever is a self-limited
febrile disease, whereas DHF-DSS is a life-threatening dis-
ease which is much more commonly observed in secondary
infections caused by a serotype of dengue virus that is
different from the serotype which caused the primary infec-
tion (3, 7). The pathogenesis of DHF-DSS is not clearly
understood. It has been speculated that augmented dengue
virus infection of Fcy receptor (FcYR)-positive monocytes by
antibodies to dengue viruses contributes to the pathogenesis
(7, 8).
We are studying human T-cell responses to dengue viruses
to understand the role of dengue virus-specific human T
lymphocytes in the pathogenesis of DHF-DSS and in recov-
ery from dengue virus infections. Dengue virus-specific
CD4+ CD8- T cells and CD4- CD8+ T cells were detected
in subjects after infection with dengue viruses (2, 13, 15).
CD8+ T cells lyse dengue virus-infected autologous cells in
a human leukocyte antigen (HLA) class I-restricted fashion
and recognize the viral envelope (E) protein or viral non-
structural proteins (2). CD4+ T cells proliferate and produce
gamma interferon (IFN--y), which up-regulates the expres-
sion of FcYRI and augments dengue virus infection in the
presence of antibody to dengue viruses (13). From these
results we hypothesized that during secondary infections the
number of dengue virus-infected monocytes is increased by
infection with dengue virus-antibody complexes and by
IFN--y, which is produced by dengue virus-specific CD4+ T
cells, and that lysis of these dengue virus-infected mono-
* Corresponding author.
cytes by CD4+ cytotoxic T lymphocytes (CTL) and CD8+
CTL may lead to DHF-DSS (14, 16). To further characterize
dengue virus-specific CD4+ T cells, we have established
CD4+ CD8- clones from a donor who had been immunized
earlier with yellow fever vaccine and was then infected with
dengue virus type 3 (15). These T-cell clones produced
IFN-y and lysed dengue antigen-cultured autologous cells.
In this paper we report the virus and dengue virus serotype
specificity and HLA restriction of these clones. Dengue
virus-specific CD4+ T-cell clones are heterogeneous, and
there are at least six patterns of virus and dengue virus
serotype specificity. HLA-DP, HLA-DQ, and HLA-DR are
all used as restriction elements. We are determining the
dengue virus proteins recognized by these T-cell clones. Of
12 clones examined to date, 7 recognize the nonstructural
protein NS3. These results suggest that these dengue virus
serotype-cross-reactive and flavivirus-cross-reactive T cells
are activated during secondary infection with a different
serotype of dengue virus from that which caused the primary
infection and that they may play an important role in the
pathogenesis of DHF-DSS.
MATERIALS AND METHODS
Viruses. Dengue virus type 1, Hawaii strain; type 2, New
Guinea C strain; type 3, CH53489 strain; and type 4, 814669
strain; yellow fever virus (YFV) (17D strain); and West Nile
virus (WNV) (ElOl strain) were used in this study. Dengue
virus types 1 and 2 were supplied by Walter E. Brandt,
Walter Reed Army Institute of Research, Washington, D.C.;
type 3 was supplied by Bruce L. Innis, Armed Forces
Research Institute of Medical Science, Bangkok, Thailand;
and type 4 was supplied by Jack McCown, Walter Reed
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Army Institute of Research. YFV was supplied by Jacob J.
Schlesinger, University of Rochester School of Medicine
and Dentistry.
Preparation of dengue virus antigens. Dengue virus anti-
gens, YFV antigen, and WNV antigen were prepared by
using dengue virus-infected Vero cells as previously re-
ported (13). Vero cells were infected with viruses at an
approximate multiplicity of infection of 1 PFU per cell and
cultured in minimal essential medium containing 2% fetal
calf serum (FCS). When 50% of the monolayer developed
cytopathic effects, the cells were removed by using cell
scrapers (Costar, Cambridge, Mass.), washed three times
with phosphate-buffered saline (PBS) at 4°C, treated with
0.025% glutaraldehyde (Sigma Chemical Co., St. Louis,
Mo.) in PBS for 15 min at 4°C, washed again three times with
PBS, and resuspended in RPMI. They were then sonicated
with a sonic dismembrator (Fisher Chemical Co.) and cen-
trifuged at 1,500 x g for 10 min. The supernatant fluid was
collected and used as the virus antigen. Control antigen was
prepared in a similar manner by using uninfected Vero cells.
Antigen (3 ml) was obtained from 15 75-cm2 flasks (Costar)
of confluent Vero cells.
Preparation of NS1 and NS3 proteins. MK2 cells were
infected with dengue virus type 3 (CH53489) at an approxi-
mate multiplicity of infection of 1 PFU per cell and cultured
for 2 days in minimal essential medium containing 8% FCS.
The medium of one of eight T150 flasks was then replaced
with minimal essential medium lacking methionine and con-
taining 0.5% FCS and 2.0 ,ug of dactinomycin per ml. One
hour later, 30 ,uCi of [35S]methionine per ml was added; the
cells were harvested 5 h later.
BHK (strain 2) cells were infected with WNV at a multi-
plicity of infection of 1, and one flask was incubated with
minimal essential medium lacking methionine and with dacti-
nomycin and [35S]methionine added as described above.
At the time of harvest, the infected cells were washed
twice with PBS and then scraped into 5 ml of PBS per flask.
The cells were pelleted at 350 x g for 3 min. The cell pellet
was resuspended in 0.24 ml (in three T150 flasks) of 0.1 M
Tris (pH 6.8) containing 0.8% sodium dodecyl sulfate (SDS).
After cell lysis the SDS concentration was diluted to 0.08%.
The cell extract was sheared seven times through a 23-gauge
needle and then seven times through a 26-gauge needle. The
extract was incubated at 37°C for 2 h with DNase (1.5
,ug/ml), and then concentrated gel sample buffer was added
to give a final concentration of 0.05 M Tris (pH 6.8), 2%
SDS, 10% glycerol, and 0.025% bromophenol blue.
The infected-cell proteins were electrophoresed on multi-
ple SDS-10% polyacrylamide gels. Protein samples were not
boiled prior to electrophoresis, so that the NS1 protein dimer
would remain intact. The gels were then wrapped in Saran
wrap and exposed to X-Omat AR film at 4°C for 5 to 7 days.
Viral protein bands (NS1 dimer and NS3) were identified by
comparison with lanes containing uninfected control cell
extracts and excised. Viral proteins were eluted electro-
phoretically by using an Elutrap (Schleicher & Schuell,
Keene, N.H.) and a buffer containing 25 mM Tris (pH 8.3),
0.1% SDS, and 192 mM glycine. SDS was removed from the
eluted protein by dialysis against PBS, and the protein
concentration was determined by the bicinchoninic acid
(BCA) microprotein assay (Pierce, Rockford, Ill.).
Human PBMC. Peripheral blood specimens were obtained
from donor A, who had been immunized with yellow fever
vaccine 2 years earlier and was infected with dengue virus
type 3 (CH53489) 1 year before the specimens were obtained
(9). Peripheral blood mononuclear cells (PBMC) were sepa-
rated by a Ficoll-Hypaque density gradient centrifugation
method (1). Cells were resuspended at 1 x 107/ml in RPMI
containing 10% FCS (GIBCO Laboratories, Grand Island,
N.Y.) and 10% dimethyl sulfoxide (Fisher Scientific Co.,
Pittsburgh, Pa.) and were cryopreserved until use (11).
Establishment of dengue virus-specific T-cell clones by using
a limited dilution method. Dengue virus-specific T-cell clones
were established as previously reported (15). PBMC (4 x
105) were cultured for 7 days with dengue virus type 2 or 3
antigen at a final dilution of 1:30 in 0.2 ml ofRPMI containing
10% human AB serum in 96-well round-bottom plates. On
day 7, blast cells were enriched by Ficoll-Hypaque density
gradient centrifugation and were cultured at concentrations
of 30, 10, 3, 1, and 0.3 cells per well with 105 gamma-
irradiated (3,000 rads) autologous PBMC in 0.2 ml of RPMI
containing 10% human AB serum, 10% T-cell growth factor
(Cellular Products, Inc., Buffalo, N.Y.), and dengue virus
type 2 or 3 antigen at a final dilution of 1:30 in 96-well
round-bottom plates. On day 14, 0.1 ml of medium was
removed from each well and 105 gamma-irradiated autolo-
gous PBMC in 0.1 ml of fresh medium with human AB
serum, T-cell growth factor, and dengue virus antigen were
added to maintain the same final concentrations described
above. On day 21, cells in wells demonstrating growth were
transferred to 48-well flat-bottom plates (Costar) and were
further cultured with 106 gamma-irradiated autologous
PBMC in 1 ml of RPMI containing 10% human AB serum,
10% T-cell growth factor, and dengue virus antigen at a
dilution of 1:30.
JK21, JK26, JK28, JK32, JK34, JK36 and JK37 were
established by using dengue virus type 3 antigen after
cloning of one cell per well. JK39, JK41, JK43, JK44, JK46,
and JK49 were established by using dengue virus type 2
antigen. JK39 was established after cloning of 0.3 cell per
well; JK41 was established after cloning of 3 cells per well;
and JK43, JK44, JK46, and JK49 were established after
cloning of 10 cells per well.
Preparation of lymphoblastoid cell lines pulsed with dengue
virus antigens. Lymphoblastoid cell lines were established
by infecting PBMC with Epstein-Barr virus from an infected
marmoset cell line supernatant (22). All the transformed cells
were cultured in RPMI containing 10% FCS. Epstein-Barr
virus was provided by Takeshi Sairenji, University of Mas-
sachusetts Medical Center.
A total of 4 x 105 lymphoblastoid cell lines were incubated
for 24 h with dengue virus antigen, YFV antigen, or WNV
antigen at a final dilution of 1:80, with purified dengue virus
type 3 NS1, dengue virus type 3 NS3, WNV NS3, or control
cell protein at a final concentration of 20 ,g/ml in 1 ml of
RPMI containing 10% FCS. Cells were washed twice with
RPMI-10% FCS, 51Cr labeled, and used as target cells.
Cytotoxicity assays. Target cells (4 x 105) were labeled
with 0.5 mCi of 51Cr (Na2CrO4) (Dupont, NEN, Boston,
Mass.) at 37°C for 45 min in 0.2 ml of RPMI-10% FCS.
Labeled cells were washed three times and suspended at 2.5
x 104/ml in RPMI-10% FCS. Then 2.5 x 103 cells in 0.1 ml
were added to each well in round-bottom microtiter plates
(Linbro Chemical Co., Hamden, Conn.). Various concentra-
tions of effector cells in 0.1 ml of RPMI-10% FCS were
added to each well to give the described effector/target
ratios. After incubation at 37°C for 6 h, the supernatant fluid
was collected from each well and counted in an automatic
gamma counter. The percent specific 51Cr release was cal-
culated by the following formula: 100 x (cpm experimental
release - cpm spontaneous release)/(cpm maximal release -
cpm spontaneous release).
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TABLE 1. Virus and dengue virus serotype specificity of CD4+ CD8- T-cell clones established from donor A
infected with dengue virus type 3a
% Specific 51Cr releaseb for:
Clone Dengue virus type: Control No
1 2 3 4 antigen antigen
Dengue virus serotype specific
JK21 1 0 20 0 0 0 0 0
JK37 1 0 57 0 0 0 0 0
Dengue virus subcomplex specific
JK36 0 55 50 15 0 0 0 0
JK46 1 68 67 27 0 0 0 0
JK44 24 65 34 0 0 0 0 0
Dengue virus serotype cross-reactive
JK32 52 65 66 55 7 8 10 10
JK34 28 54 52 23 0 0 0 0
JK39 39 62 67 31 0 0 0 0
JK41 12 43 39 12 0 0 0 0
Flavivirus cross-reactive
JK28 24 46 41 25 0 23 0 0
JK26 23 40 41 19 19 55 0 0
JK43 22 31 34 27 37 43 0 0
JK49 34 60 57 26 29 50 0 0
a A total of 2.5 x 103 target cells was incubated with effector cells for 6 h.
b The percent specific 51Cr release was calculated by using the formula described in Materials and Methods. The effector/target ratio was 3:1 for JK21 and JK43;
4:1 for JK41; 6:1 for JK36, JK37, JK46, JK44, JK32, JK34, JK39, and JK49; 7:1 for JK26; and 12:1 for JK28. Underlines indicate significant levels of lysis.
Antibody blocking of the lysis of dengue virus antigen-
cultured target cells. Monoclonal antibodies B7/21.7, S3/4,
and OKIal recognize HLA-DP, HLA-DQ, and HLA-DR
determinants, respectively. Monoclonal antibody W6/32 rec-
ognizes a framework determinant of HLA-A, HLA-B, and
HLA-C. B7/21.7 and S3/4 were kindly provided by Nancy
Reinsmoen, University of Minnesota, Minneapolis. OKIal
was purchased from Ortho Diagnostic Systems, Inc., Rari-
tan, N.J. W6/32 was purchased from Accurate Biochemical
Co., Westbury, N.Y. A total of 2.5 x 103 51Cr-labeled target
cells in 0.1 ml were incubated with 0.05 ml of 1:20 diluted
monoclonal antibodies for 30 min. The effector cells were
then added in 0.05 ml, and the mixture was incubated for 6 h.
The percent specific 51Cr release was determined as de-
scribed above.
Phenotypic analysis. Anti-Leu-2 (4), anti-Leu-3 (4), and
anti-Leu-4 (18) antibodies were used as antibodies to CD8,
CD4, and CD3, respectively. Anti-Leu-2, anti-Leu-3, and
anti-Leu-4 antibodies were purchased from Becton Dickin-
son Co., Mountain View, Calif. Clones were typed with
fluorescein isothiocyanate-conjugated monoclonal antibod-
ies by direct immunofluorescence methods as described
earlier (12). The percentage of antigen-positive cells was
determined by using a fluorescence-activated cell sorter (no.
440; Becton Dickinson Co.).
RESULTS
Virus and dengue virus serotype specificity of CD4+ T-cell
clones. Dengue virus-specific T-cell clones were established
from lymphocytes of donor A by using limiting-dilution
methods as described above. Seven clones were established
by using dengue virus type 3 antigen (15), and six clones
were established by using dengue virus type 2 antigen.
Phenotypic analyses with monoclonal antibodies showed
that all the clones have CD3+ CD4+ CD8- phenotypes.
These clones were examined for their virus and dengue
virus serotype specificities in cytotoxic activities (Table 1).
JK21 and JK37 lysed target cells cultured with dengue virus
type 3 antigen, but did not lyse target cells cultured with
dengue virus type 1, 2, or 4 or YFV or WNV antigen.
Therefore, they are dengue virus serotype specific. JK36 and
JK46 lysed target cells cultured with dengue virus types 2, 3,
and 4 antigens, but did not lyse target cells cultured with
dengue virus type 1, YFV, or WNV antigen. JK44 lysed
target cells cultured with dengue virus types 1, 2, and 3
antigens, but did not lyse target cells cultured with dengue
virus type 4, YFV, or WNV antigen. Therefore, these three
clones are dengue virus subcomplex specific. Four clones,
JK32, JK34, JK39 and JK41, lysed target cells cultured with
dengue virus antigen of four serotypes, but did not lyse
target cells cultured with YFV or WNV antigen. Therefore,
they are dengue virus serotype cross-reactive.
JK28 lysed target cells cultured with dengue virus antigen
of four serotypes and WNV antigen, but did not lyse target
cells cultured with YFV antigen. JK26, JK43, and JK49
lysed target cells cultured with dengue virus antigen of four
serotypes and YFV and WNV antigens. Therefore, these
clones are flavivirus cross-reactive.
These results indicate that dengue virus-specific CD4+ T
cells are heterogeneous in virus and dengue virus serotype
specificity and that there are at least six patterns of speci-
ficity.
HLA restriction in the lysis of target cells by CD4+ T-celi
clones. HLA restriction of the lysis of target cells by dengue
virus-specific CD4+ T-cell clones were examined by using
monoclonal antibodies to HLA molecules (Table 2). Mono-
clonal antibody to HLA-DP inhibited the lysis of target cells
by dengue virus type 3-specific clone JK37; dengue virus
serotype-cross-reactive clones JK32, JK34, JK39, and JK41;
and flavivirus-cross-reactive clones JK26, JK28, and JK49.
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TABLE 2. HLA restriction of lysis of dengue virus type 3 antigen-cultured target cells by CD4+ T-cell clonesa
% Specific 5"Cr release for":
Clone
No antigen Anti-HLA-DP Anti-HLA-DQ Anti-HLA-DR
Dengue virus serotype specific
JK21 22 21 26 6
JK37 55 5 48 26
Dengue virus subcomplex specific
JK36 25 26 4 20
JK46 45 47 8 41
JK44 51 46 54 14
Dengue virus serotype cross-reactive
JK32 83 7 80 71
JK34 87 1 83 77
JK39 46 1 48 45
JK41 56 7 47 40
Flavivirus cross-reactive
JK28 91 11 78 77
JK26 64 1 64 69
JK43 56 49 55 59
JK49 53 1 41 57
a A total of 2.5 x 103 target cells were incubated with effector cells for 6 h in the presence of monoclonal antibodies at final dilution of 1:80.
b B7/21.7, S3/4, and OKIal were used as anti-HLA-DP, anti-HLA-DQ, and anti-HLA-DR, respectively. The percent specific 51Cr release was calculated by
using the formula described in Materials and Methods. The effector/target ratio was 4:1 for JK43; 5:1 for JK21, JK39, and JK46; 6:1 for JK37, JK26, JK32, JK44,
and JK49; 7:1 for JK36; 11:1 for JK28; 14:1 for JK34; and 15:1 for JK41. Underlines indicate significant inhibition by each antibody.
Monoclonal antibody to HLA-DQ inhibited the lysis of
target cells by dengue virus subcomplex-specific clones
JK36 and JK46. Monoclonal antibody to HLA-DR inhibited
the lysis of target cells by dengue virus type 3-specific clone
JK21 and subcomplex-specific clone JK44. Interestingly, the
lysis of target cells by flavivirus-cross-reactive clone JK43
was not inhibited by any of the three monoclonal antibodies
to HLA class II or by an antibody to HLA class I. However,
the lysis by JK43 was inhibited by a mixture of anti-HLA-
DP, HLA-DQ, and HLA-DR antibodies and by an antibody
to CD3 (data not presented).
These results indicate that dengue virus-specific CD4+
T-cell clones are HLA class II restricted and that HLA-DP,
HLA-DQ, and HLA-DR are used as restriction elements by
the various clones.
Recognition of NS3 by dengue virus-specific T-cell clones.
We have previously reported that NS3 induces high levels of
proliferation responses of donor A PBMC in bulk cultures
(17). We next tried to determine whether CD4+ T-cell clones
recognize purified NS3 protein (Table 3). The dengue virus
type 3-specific clone JK37, the subcomplex-specific clones
JK36 and JK46, and the serotype-cross-reactive clones
JK32, JK34, and JK39 lysed target cells cultured with NS3
protein purified from dengue virus type 3-infected cells, but
did not lyse target cells cultured with NS1 protein purified
from dengue virus type 3-infected cells or NS3 from WNV-
infected cells. The flavivirus-cross-reactive clone JK43 lysed
target cells cultured with NS3 obtained from dengue virus
type 3-infected cells or from WNV-infected cells, but did not
lyse target cells cultured with NS1 obtained from dengue
virus type 3-infected cells.
Lysis of target cells cultured with the NS3 protein of
dengue virus type 3 by JK34 and JK39 was inhibited by
antibody to HLA-DP (data not presented). JK26, JK28,
JK41, JK44, and JK49 did not lyse target cells cultured with
NS1 or NS3 proteins (Table 3). These results suggest that the
NS3 protein contains multiple epitopes recognized by den-
gue virus-specific CD4+ T cells of various serotype specific-
ities.
DISCUSSION
In this article we have reported that (i) Dengue virus-
specific, human CD4+ CD8- T-cell clones are heteroge-
neous with at least six patterns of virus and serotype
specificities; (ii) HLA restriction of cytotoxicity by dengue
virus-specific CD4+ T-cell clones is also heterogeneous with
HLA-DP, HLA-DQ, and HLA-DR, each being used as
restriction elements by individual CTL clones; and (iii) 7 of
the 12 clones examined recognize epitopes on the NS3
protein. Table 4 gives a summary of these results.
We have previously reported that most of these T-cell
clones produce IFN--y after stimulation with dengue virus
antigen (15) and that IFN--y, which up-regulates FcYR,
augments dengue virus infection of Fc,R-positive monocytic
cells in the presence of dengue virus antibodies. From these
observations we hypothesized that CD4+ T cells may con-
tribute to the pathogenesis ofDHF-DSS by producing IFN--y
and by lysing dengue virus-infected monocytes (14, 16).
Epidemiological studies have shown that DHF-DSS is much
more commonly observed during a secondary infection with
a different serotype from that which caused the primary
infection (3, 7). Although the specificities of the clones may
not accurately reflect the specificities of the in vivo, un-
cloned, dengue virus-specific CTL, the identification of
serotype-cross-reactive and flavivirus-cross-reactive CD4+
T cells supports the possibility that such T cells are activated
during secondary infection with a dengue virus of a heterol-
ogous serotype and that these T cells contribute to the
pathogenesis of DHF-DSS.
Of 13 clones, 7 were found to recognize the NS3 protein.
This result is consistent with our previous observation that
purified NS3 induced a high level of proliferation of PBMC
from donor A in bulk cultures (17). The clones which
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TABLE 3. Recognition of NS3 protein by dengue virus-specific CD4+ T-cell clonesa
% Specific 51Cr release forb:
Clone Dengue Dengue WNV Control cell Dege WNV No
virus type 3 virus type 3 protein virus type 3 antigen antigen
Dengue virus serotype specific
JK37 2 13 2 NDC 56 0 1
Dengue virus subcomplex specific
JK36 10 40 ND 15 87 ND 19
JK46 7 20 0 ND 75 ND 7
JK44 0 1 0 ND 47 0 0
Dengue virus serotype cross-reactive
JK32 11 27 10 14 77 10 6
JK34 2 14 0 0 79 0 0
JK39 7 19 0 ND 42 ND 6
*JK41 0 3 ND 4 66 ND 0
Flavivirus cross-reactive
JK28 2 7 0 1 70 30 0
JK26 0 5 0 0 60 49 0
JK43 7 25 84 8 78 93 0
JK49 7 5 0 2 77 72 0
a A total of 2.5 x 103 target cells were incubated with effector cells for 6 h.
b Autologous Epstein-Barr virus-transformed cells were cultured with dengue virus type 3 NS1, dengue virus type 3 NS3, WNV NS3, and control cell protein
at final concentration of 20 ,ug/ml with and dengue virus type 3 and WNV antigens at 1:80 for 24 h prior to addition of effector T cells. The percent specific 51Cr
release was calculated by using the formula described in Materials and Methods. The effector/target ratio was 4:1 for JK32; 6:1 for JK26, JK37, JK39, and JK44;
7:1 for JK46; 8:1 for JK41 and JK43; 4:1 for JK49; 10:1 for JK28 and JK34; and 11:1 for JK36. Underlines indicate significant levels of lysis.
c ND, Not done.
recognize NS3 are heterogeneous. They include a dengue
virus type 3-specific clone (JK37), subcomplex-specific
clones (JK36 and JK46), dengue virus serotype-cross-reac-
tive clones (JK32, JK34, and JK39) and a flavivirus-cross-
reactive clone (JK43). It was surprising to find that NS3 is so
immunogenic since it is one of the seven flavivirus nonstruc-
tural proteins and is tightly attached to endoplasmic reticular
membranes in infected cells (6). NS3 is composed of 618
TABLE 4. Summary of dengue virus-specific CD4+ CD8-
T-cell clones
Virus and serotype HLA oProtein
specificitya Clone restric- recognzed"tion NS3 NS1
Serotype specific
D3 JK21 DR NT NT
JK37 DP + -
Subcomplex specific
D2, D3, D4 JK36 DQ + -
JK46 DQ + -
D1, D2, D3 JK44 DR - -
Dengue virus serotype cross-reactive
D1, D2, D3, D4 JK32 DP + -
JK34 DP + -
JK39 DP + -
JK41 DP - -
Flavivirus cross-reactive
D1, D2, D3, D4, WNV JK28 DP - -
Dl, D2, D3, D4, YFV, WNV JK26 DP - -
JK43 ?c + -
JK49 DP - -
aDl, D2, D3, D4, Dengue virus types 1, 2, 3, and 4, respectively.
b+, Recognition; -, no recognition; NT, not tested.
c ?, Undetermined.
amino acids (19) and has a mass of 67 kDa. It is hydrophilic
and has a net positive charge. It contains conserved epitopes
characteristic of helicases (5), and it has also been reported
to have proteinase activity (20). The two largest flavivirus
nonstructural proteins, NS5 (96 kDa), which is thought to be
the viral replicase, and NS3, are the most highly conserved
among the flaviviruses. There is a 75% homology between
the amino acid sequence of the NS3 of dengue virus type 4
(the 814669 strain) and that of dengue virus type 2 (New
Guinea C strain) (10), 62% homology between the NS3s of
dengue virus type 4 and WNV, and 51% homology between
the NS3s of dengue virus type 4 and YFV (19). The presence
of dengue virus subcomplex-specific, serotype-cross-reac-
tive, and flavivirus-cross-reactive T-cell clones is consistent
with the high level of amino acid conservation observed for
NS3.
The observation that T-cell clones with four different
serotype specificities recognize NS3 strongly suggests that
NS3 has at least four epitopes recognized by dengue virus-
specific CD4+ T cells. It will be important to localize these
multiple T-cell epitopes on NS3. This will be performed by
using recombinant vaccinia viruses containing truncated
dengue virus NS3 genome and with synthetic peptides. It is
clear that NS3 is not the only protein which contains CD4+
T-cell epitopes, since some of the CTL clones do not
recognize either NS3 or NS1. Therefore, identification of
other proteins which contain epitopes recognized by these
T-cell clones also remains to be done.
We have observed that the viral proteins recognized by
dengue virus-specific murine CTL vary with the mouse
strains (21). Therefore, it is likely that dengue virus-specific
T cells from other donors who possess different HLA alleles
from those of donor A will recognize different epitopes on
dengue virus proteins. To gain a complete understanding of
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the T-cell response to dengue viruses in humans, it will be
necessary to define the epitopes recognized by dengue
virus-specific T cells from individuals with different major
histocompatibility complex antigens as well as from individ-
uals infected with various dengue viruses.
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